Petal announces additional investment as momentum builds around incisionless surgery.

For centuries now, surgery has been about invasive and painful manipulation of tissue with one or more tools. Even the most recent advances in the field have not been able to break this fundamental constraint. Petal is changing that. We are developing a new approach to surgery using acoustic liquefaction — delivered through a unique form of histotripsy called Millisecond Pulse Histotripsy — combined with AI and robotics.

We call it incisionless surgery: a new standard of care that eliminates cutting, pain, trauma, and many of the risks inherent to traditional surgery. No cuts. No burns. No toxicity. Then the body heals itself naturally.

Since coming out of stealth in October 2025, momentum around our vision has continued to build.

Today, we are announcing additional investment as investor demand continues following our oversubscribed Series A in 2025, bringing our total funding to over $25M to date. This financing is led by a prominent high net worth investment firm, with repeat participation from Draper Associates, Actions Capital (formerly K50 Ventures), and Fong’s Family Foundation.

The round also coincides with another major milestone for the company: we are honored to share that Dr. Frederic H. Moll, a pioneer of surgical robotics, has joined our Board of Directors, further strengthening our leadership as we advance our approach to incisionless surgery.

“The companies we back are building technologies that sound futuristic — until they suddenly become foundational. They are grounded in real science and engineering, with transformative applications likely to arrive faster than most people expect. Petal is one of those missions. By making surgery incisionless — no cuts, no heat, no toxicity — the body can heal itself naturally. We’re excited to support a future where healing doesn’t begin with harm and where everyone has dignified access to world-class healthcare.”
— Tim Draper, Founder of Draper Associates, Draper University, and the Draper Venture Network.

This additional funding will accelerate our path to patients through focused research and development and the continued recruitment of world-class talent.

“Prash lost his father to surgical complications. That loss became a mission — and that mission became Petal. From the moment we met him, it was clear he wasn’t building an incremental improvement — he was starting over. Three investments later, we’re more convinced than ever that he is the right person to lead the team that will make incisionless surgery the new standard of care.” — Ryan Bloomer, Founder, Actions Capital (formerly K50 Ventures).

We’re excited to see continued support of our human-centric approach to healthcare. We envision a world where incisionless surgery becomes the standard of care, accessible to patients in all communities — modern and developing — while eliminating many of the risks and complications associated with traditional surgery.

We invite you to stay close, as there will be more from us in the coming months. Please follow us on LinkedIn, Twitter/X, and Instagram.

About Petal

Petal Surgical is pioneering a new field of incisionless surgery through Millisecond Pulse Histotripsy, combined with robotics and AI. The company has raised over $25M to date, including an oversubscribed Series A in 2025 co-led by K50 Ventures and TSVC, with participation from ShangBay Capital and Dr. Frederic H. Moll. A subsequent financing was led by a prominent high-net-worth investment firm, with repeat participation from Draper Associates, Actions Capital, and Fong’s Family Foundation.

Founded by Prash Chopra (image-guided surgery engineer), Dr. Bowen Jiang (neurosurgeon), Dr. Nicholas Theodore (robotic-assisted spine surgery pioneer), and Rony Abovitz (Founder of MAKO Surgical, SynthBee, and MagicLeap), Petal is advancing a safer, incisionless future for surgery worldwide.

Planet Earth, we’re Petal. And we are making healing human.

View fullsize

We live in a world where unfortunately, at least 2 billion people across the globe lack access to safe surgical care . And even those of us who do have access to care, about 4 million die as a result of surgery or complications stemming from invasive procedures each year. 

Modern surgery still requires incisions, creating more harm before the healing can begin, not to mention the lack of access related to all the complexity that comes with the entire surgical setup. The status quo for surgery as we know it today still means that patients experience pain, trauma, complications, and sometimes, even death, regardless of access. 

But what if Surgery did not require cuts? How would access, and patient experience change? 

We imagine that world. And because of recent advances on multiple technology fronts, we are realizing a better way to enable surgery – a way to make healing human. 

At Petal, we see a world where healing doesn’t begin with harm. We’re developing a new approach to surgery using acoustic liquefaction (a unique form of histotripsy), AI, and robotics. We call it incisionless surgery  — a new standard of care that eliminates cutting, pain, trauma, and much of the typical risks inherent to traditional surgery from most procedures. No cuts, no burns, no toxicity. Then the body heals itself naturally. 

On our way to take our solution to the patients, we’ve raised nearly $20M in total funding, including a $10M Series A that was co-led by K 50 Ventures and TSVC, with participation from Draper’s, ShangBay Capital, Eliot Horowitz, Dr. Frederic H. Moll and other notable VCs and industry pioneers. 

“Lack of surgery access is a major obstacle to proper healthcare, and Petal has built something transformative for incisionless surgery. This is a great example of how AI and robotics can have an incredible impact on all aspects of life.”
– Eliot Horowitz, Founder and CEO, Viam

This funding will not only allow us to scale our ambitious goal and technology, but continue to bring on world class talent. Our technology is built with the input of premier physicians, respected scientists and world class engineers. The result is a treatment that’s more effective and precise for patients, and a solution that is less bulky and more intuitive for operators to use. Our solution works with the body’s natural abilities to heal by creating vapor filled cavities one at a time, that allow for clear and connected treatment regions, with more opportunities to break down tougher tissues. 

"At K50, we invest in consequential companies that propel the world forward. When it comes to health, we believe everyone, everywhere should have access to the care they need to live healthier, longer lives. Petal’s approach to incisionless surgery aligns powerfully with that vision. By reimagining surgical care from the ground up, Petal is making treatment safer, more accessible, and more equitable for patients across the globe."
– Ryan Bloomer, Founder and Managing Partner of K50 Ventures.

The Petal team is composed of leaders and pioneers of their respective fields who have come together to collaborate on a solution that is  bigger than the sum of our parts. We’ve assembled a team with the collective belief that a better, and human, approach to surgery is possible. 

We’re excited to emerge out of stealth and begin to share more about the innovation and human-centric approach we’re bringing to the world of healthcare. We can clearly see a world where incisionless surgery has become the norm and standard, in all communities - modern and developing, being an accessible yet hi-tech option to patients and eliminating risks and complications that are associated with surgery.

We invite you to stay close, as there will be more from us in the coming months. Please follow Petal on LinkedIn, Twitter/X, and Instagram.

About Petal:

Petal Surgical is pioneering a new field of incisionless surgery via a distinct form of histotripsy using robotics and AI. The company has raised $17.7 million to date, including a Series A financing round that was co-led by K50 Ventures and TSVC, supported by ShangBay Capital, and Dr. Frederic H. Moll, a pioneer in surgical robotics.

The company was founded by Prash Chopra, a seasoned image guided surgery engineer, along with Dr. Bowen Jiang (a neurosurgeon), Dr. Nicholas Theodore (a pioneer of robotic assisted spine surgery), and Rony Abovitz (founder of MAKO Surgical and MagicLeap).